I am not sure why you got thumbs down, but biotech's are long term investments. You get a thumbs up from me.
I would like to thank both you and w999surf and a few others. This is the most factual and informative board I've visited on yahoo. The time reading the posts have been well spent. Thanks!
HERE IS A LINK TO CONTENTS OF EMAIL: copy and paste in your browser window.
The Company intends to continue the development of Samcyprone™ by completing Phase 2a studies and initiating Phase 2b studies in 2016. It is noteworthy that the mechanism of action of Samcyprone™ is linked to DPCP's ability to alter the expression of multiple genes and miRNAs involved in the immune response. Our work with Samcyprone™ should also allow us to discover specific targets for the potential treatment of immunological disorders that are relevant to the skin as well as various systemic diseases. This approach may result in the development of sd-rxRNA® or other drugs that are more potent and selective for various indications, including the treatment of alopecia areata, warts or cutaneous metastases of malignant melanoma.
Advancements within clinical and pre-clinical programs
RXi Pharmaceuticals' first clinical program involves RXI-109, an sd-rxRNA® compound, developed for the reduction of dermal scarring. RXI-109 is designed to reduce the expression of connective tissue growth factor (CTGF), a critical regulator of biological pathways involved in fibrosis, including scar formation in the skin. The first clinical trials with RXI-109 (RXI-109-1201 and RXI-109-1202) showed excellent safety and tolerability with ascending single and multiple doses, as well as dose dependent effects on the CTGF protein and on the mRNA that controls production of this protein.
Three Phase 2a clinical trials are currently underway to evaluate the effectiveness and safety of RXI-109 on the outcome of scar revision surgeries performed on hypertrophic scars resulting from lower abdominal surgeries (RXI-109-1301), to evaluate the effectiveness and safety RXI-109 in healthy subjects who undergo an elective surgical excision of two similarly sized and placed keloids (RXI-109-1401) and the outcome of scar revision surgeries performed on hypertrophic scars (RXI-109-1402).
I just got a Happy Holiday message from all those at RXII. So I would like to wish Happy Holidays and a prosperous New Year to all those at RXII and all who visit this message board. Merry Christmas All!
I makes a Huge difference to the small companies who are not yet profitable. That 2.5 percent of revenue comes at the expense of research and development. Here in Central New York State 80 jobs were lost to Mexico because of it. The medical device tax is a pimple of the #$%$ of innovation!
I don't look at this board often. But after yesterdays move, I decided to have a look. I am long TRXC and TITXF (Titan Medical). I believe they will both offer competition to ISRG. I previously owned 26000 shares of Computer Motion which became 6800 shares of ISRG after they merged in 2003. I sold my last shares of ISRG at $500 when the lawsuits and bashing started. As you can see I have followed robotic assisted surgery for several years. I look at these boards for information. Those that go to these boards to just bash stocks are jerks who offer nothing of substance to the world. IMHO, they are pimples on the backside side of progress!
Maybe Varian is not the 900 pound Gorilla it is cracked up to be.... The following is from ZACKS
" Why the Downgrade?
The downgrade primarily reflects Varian’s challenging near-term outlook. Both Oncology and Imaging segments of the company are facing significant headwinds. Moreover, sluggish European market trends will remain an overhang. To add to the woes, gross margin is expected to remain flat owing to unfavorable geographic mix and significant pricing pressure in the U.S.
For the first quarter of fiscal 2015, Varian expects combined revenues from Oncology Systems and Imaging Components businesses as well as proton orders, currently in backlog, to grow 0%–2%, which lags our expectations.
[ Meanwhile, intensifying competition from the likes of Siemens and Philips as well as smaller and more specialized radiation therapy equipment manufacturers such as Elekta and Accuray Inc. (ARAY - Analyst Report) is a growing concern. ]
Varian continues to invest in developing new platforms and technologies in order to improve its customer base and competitive position. Although these investments will help improve its long-term growth prospects, it will continue to hurt its bottom line over the next several quarters. Also, higher operating expenses will remain a drag on profits in the near term.
Over the last 60 days, 4 out of 5 analysts covering Varian have lowered their first-quarter fiscal 2015 earnings estimates due to growing headwinds. The Zacks Consensus Estimate has declined 19 cents (18%) to 87 cents over the period, which is better than Varian’s guided range of 76 cents to 80 cents (including restructuring expenses). "
You are kidding, right? ISORAY revenues: 2010 5.29M, 2011 5.24M, 2012 5.07M, 2013 4.53M and 2014 4.22M. They are miniscule and headed in wrong direction.
If you thing Varian should buy Tomo technology... you must think Tomo has something to offer. Often companies have a not invented here mentality.
Surely your jest. Past 5 years yearly revenue: 2010 5.29M, 2011 5,24M, 2012 5.07M, 2013 4.53M, 2014 4.22M. Miniscule sales headed in wrong direction.